TONMYA Secures Commercial Payer Coverage, Expanding Access to 35 Million U.S. Patients
Summary
Tonix Pharmaceuticals announced it has secured commercial payer coverage for its fibromyalgia drug, TONMYA®, through an agreement with a leading group purchasing organization (GPO). This deal, effective May 1, 2026, provides access to approximately 35 million U.S. commercial lives, representing 20% of the U.S. commercial market. This is a significant positive development for TONMYA, which was FDA-approved in August 2025 and commercially launched in November 2025. The news is particularly impactful given the company's recent preliminary Q1 2026 results, which highlighted increased cash burn and a going concern warning in its latest 10-K. Expanding market access for TONMYA, a first-in-class non-opioid analgesic, is crucial for Tonix's revenue generation and addressing its financial challenges. Traders will closely watch for further payer agreements and the impact of this expanded access on TONMYA sales and the company's overall financial trajectory.
At the time of this announcement, TNXP was trading at $13.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $191.8M. The 52-week trading range was $11.60 to $69.97. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.